Tetracycline

General Information

Formulary antimicrobial: Use in accordance with Trust guidelines

Open all

Dose in renal impairment

Avoid if possible in renal impairment due to its potential nephrotoxicity and increased risk of azotaemia, hyperphosphataemia and acidosis

eGFR (mL/min/1.73m²)	Oral dose
10-50	Dose as in normal renal function
Less than 10	Maximum 250mg QDS
HD/HDF/High Flux/PD	Dose as in eGFR less than 10ml/min/1.73m². Not dialysed.

Use in hepatic impairment

Use with caution in patients with hepatic impairment and those receiving potentially hepatotoxic drugs; avoid high doses in these patients.

Contraindicated in pregnancy and breastfeeding. Discuss with pharmacy.

Cautions: May increase muscle weakness in patients with myasthenia gravis and may exacerbate systemic lupus erythematosus.
Monitor full blood count, renal function and liver function periodically in patients on long term therapy.

Summary of Product Characteristics (SPC) for Tetracycline Tablets BP 250mg. Accessed via www.medicines.org.uk 26/03/18. Last updated 31/01/2017
The Renal Drug Database. Tetracycline. Accessed via renaldrugdatabase.com 15/1/19. Last updated 1/3/18
BNF online accessed via www.medicinescomplete.com 15/1/19; last updated 14/11/18